AzurRx BioPharma, Inc. (AZRX) Research

AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).

Market snapshot

Symbol
AZRX
Price
$3.45
Day change
+2.07%
Market cap
$3.4M
P/E ratio
-1.76x
52-week range
3.38-3.66
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Atreca, Inc. (BCEL)
  • Altamira Therapeutics Ltd. (CYTO)
  • Gritstone bio, Inc. (GRTS)
  • Idera Pharmaceuticals, Inc. (IDRA)
  • Lisata Therapeutics, Inc. (LSTA)
  • Onconetix, Inc. (ONCO)
  • Q32 Bio Inc. (QTTB)
  • RVL Pharmaceuticals plc (RVLP)

Recent insider activity

  • Coelho Mary Theresa — A-Award (10310 shares) on 2021-09-09
  • Coelho Mary Theresa — trade (0 shares) on 2021-08-11
  • Pennington James — A-Award (100000 shares) on 2021-07-09
  • Schneiderman Daniel H — A-Award (250000 shares) on 2021-06-30
  • Schneiderman Daniel H — A-Award (35006 shares) on 2021-06-30

Open AzurRx BioPharma, Inc. (AZRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.